79 related articles for article (PubMed ID: 37958905)
1. Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions.
Reddy D; Kumavath R; Barh D; Azevedo V; Ghosh P
Molecules; 2020 Aug; 25(16):. PubMed ID: 32784680
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Cardiac Glycosides as Potential Drugs: Current and Future Scope for Cancer Therapeutics.
Kumavath R; Paul S; Pavithran H; Paul MK; Ghosh P; Barh D; Azevedo V
Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572488
[TBL] [Abstract][Full Text] [Related]
3. The mechanistic role of cardiac glycosides in DNA damage response and repair signaling.
Ainembabazi D; Zhang Y; Turchi JJ
Cell Mol Life Sci; 2023 Aug; 80(9):250. PubMed ID: 37584722
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome Profiling of Cardiac Glycoside Treatment Reveals EGR1 and Downstream Proteins of MAPK/ERK Signaling Pathway in Human Breast Cancer Cells.
Pavithran H; Kumavath R; Ghosh P
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958905
[TBL] [Abstract][Full Text] [Related]
5. Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways.
Reddy D; Kumavath R; Ghosh P; Barh D
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31783627
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
7. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
[TBL] [Abstract][Full Text] [Related]
8. Peruvoside, a Cardiac Glycoside, Induces Primitive Myeloid Leukemia Cell Death.
Feng Q; Leong WS; Liu L; Chan WI
Molecules; 2016 Apr; 21(4):534. PubMed ID: 27110755
[TBL] [Abstract][Full Text] [Related]
9. TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.
Crawford NT; McIntyre AJ; McCormick A; D'Costa ZC; Buckley NE; Mullan PB
Oncogene; 2019 Aug; 38(31):5971-5986. PubMed ID: 31253870
[TBL] [Abstract][Full Text] [Related]
10. Friend or Foe: Regulation, Downstream Effectors of RRAD in Cancer.
Sun Z; Li Y; Tan X; Liu W; He X; Pan D; Li E; Xu L; Long L
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979412
[TBL] [Abstract][Full Text] [Related]
11. CDK2AP1 influences immune infiltrates and serves as a prognostic indicator for hepatocellular carcinoma.
Che Y; Wang G; Xia Q
Front Genet; 2022; 13():937310. PubMed ID: 36105112
[No Abstract] [Full Text] [Related]
12. Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y; Zhang H; Merkher Y; Chen L; Liu N; Leonov S; Chen Y
J Hematol Oncol; 2022 Aug; 15(1):121. PubMed ID: 36038913
[TBL] [Abstract][Full Text] [Related]
13. GLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists.
Deo SVS; Sharma J; Kumar S
Ann Surg Oncol; 2022 Oct; 29(11):6497-6500. PubMed ID: 35838905
[TBL] [Abstract][Full Text] [Related]
14. Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis.
Titus HE; Xu H; Robinson AP; Patel PA; Chen Y; Fantini D; Eaton V; Karl M; Garrison ED; Rose IVL; Chiang MY; Podojil JR; Balabanov R; Liddelow SA; Miller RH; Popko B; Miller SD
Glia; 2022 Oct; 70(10):1950-1970. PubMed ID: 35809238
[TBL] [Abstract][Full Text] [Related]
15. Drug Repurposing in Cancer Therapy: Influence of Patient's Genetic Background in Breast Cancer Treatment.
Rodrigues R; Duarte D; Vale N
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457144
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
